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1 |  INTRODUCTION
Follicular lymphoma (FL) is an indolent subtype of 
non‐Hodgkin lymphoma (NHL). Transformation of FL 
(TL) to an aggressive lymphoma is a well‐recognized phe-
nomenon. FLs most commonly transform to diffuse large 
cell lymphoma (DLBCL).1 Based on literature search, FLs 
transforming to lymphoblastic leukemia/lymphoma with a 
double‐hit or triple‐hit (ie, MYC translocation with BCL2 
and/or BCL6 rearrangement) is an extremely rare phenome-
non.2 Lymphoma involvement of the eye is uncommon,3 and 
to the best of our knowledge, this is the first reported case of 
a FL transforming to a double‐hit (MYC and BCL2 rearrange-
ment) B‐lymphoblastic lymphoma.
2 |  CASE
A 66‐year‐old man with extensive lymphadenopathy (chest, 
abdomen, and inguinal lymph nodes) and splenomegaly was 
diagnosed with FL, predominantly grades 1‐2 with focal 
areas of grade 3A, Stage IV, with high‐risk FL International 
Prognostic Index 2 (FLIPI2) score. He had a good response 
to bendamustine and rituximab. Three months into his 
treatment, he noticed left eye swelling and visual disturbance. 
Clinical examination revealed erythematous left orbit with 
restricted extra‐ocular movements and elevated Intraocular 
pressure (IOP). MRI was highly concerning for orbital cel-
lulitis with a secondary anterior displacement of left globe. In 
the emergency room, ophthalmology performed canthotomy 
and cantholysis to decrease IOP and broad‐spectrum antibiot-
ics were initiated for suspected orbital cellulitis.
On the following day, orbitotomy revealed a firm mass 
compressing the optic nerve. An excisional biopsy of this mass 
was obtained. Subsequently, the patient received steroids due to 
optic nerve compression and antibiotics were discontinued. He 
later received radiation therapy the following day. Excisional bi-
opsy of the orbital mass revealed a B‐lymphoblastic lymphoma 
(Table 1; Figure 1), entirely comprising of blastoid B cells, pos-
itive for CD19, CD10, TdT, CD38, negative for CD3, CD5, 
CD11c, and CD20 with Kappa light chain restriction (partial, 
very dim). Cytogenetics/FISH analysis also demonstrated si-
multaneous presence of MYC and BCL2 translocation. In light 
of the patient's history of FL, this B‐lymphoblastic leukemia/
lymphoma is presumably a transformed lymphoma. Further 
diagnostic workup showed the cerebrospinal fluid involve-
ment by B‐lymphoblastic lymphoma. There was no evidence 
of lymphoma/leukemia in the bone marrow. Subsequently, he 
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Key Clinical Message
Transformation of lymphoma is an infrequent phenomenon, and involvement of the 
eye as such is even uncommon. Histological transformation in patients with follicu-
lar lymphoma who were previously treated with immune‐chemotherapy carry a poor 
outcome. Here, we illustrate such a case with aggressive histological transformation 
from a low‐grade lymphoma.
K E Y W O R D S
chemotherapy, follicular lymphoma (FL), monoclonal antibodies, non‐hodgkin lymphoma (NHL), ocular 
lymphoma, transformation
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received intrathecal cytarabine and methotrexate for leptome-
ningeal carcinomatosis. He was also started on systemic che-
motherapy with HyperCVAD (cyclophosphamide, Vincristine, 
Adriamycin, and dexamethasone). Unfortunately, the patient 
could not tolerate intensive chemotherapy after two cycles of 
therapy and decided to enroll in hospice care.
3 |  DISCUSSION
Transformation of lymphoma (TL) is an infrequent phe-
nomenon and has been reported in approximately 30% of 
FL.2 TL also occurs in marginal zone lymphoma and lym-
phoplasmacytic lymphoma.4 The transformation of FL to a 
B‐lymphoblastic lymphoma along with a double‐ or triple‐hit 
is extremely rare and carries dismal prognosis. Histological 
transformation in patients with FL who previously treated 
with immunochemotherapy might carry a poor outcome that 
may deserve intensive salvage therapy including autologous 
stem cell transplant.5
3.1 | The incidence of TL and its 
outcomes and relation to rituximab
Several large studies reported the incidence of TL in FL, 
mainly in the prerituximab era, showing a 5‐ and 10‐year risk 
of 15% and 30%, respectively, with an estimated incidence 
rate of 3% per year. The outcome for patients with TL was 
poor with median survival of 1‐2 years and reported 10‐year 
survival for patients with nontransformed FL of 75%, as op-
posed to 36% in patients with evidence of transformation.6,7
After the wide adoption of rituximab in the management 
of NHL, the incidence and outcomes of TL were restudied. 
The incidence of TL was ranging between 2% per year8 and 
6% every 2 years.9 Initial treatment with rituximab was as-
sociated with significantly reduced transformation risk vs 
patients who were only initially observed (3.2% vs 14.4%, 
respectively).8,9 Survival of TL in the postrituximab era is 
evidently better than what was reported in prerituximab era. 
Wagner et al9 reported that the 5‐year survival for patients 
T A B L E  1  Flow cytometry markers
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in the postrituximab era is significantly improved, TL had 
a survival rate of 75%, and nontransformed lymphomas had 
survival of 85%.
3.2 | Clinical prognostics of TL
Studies have been done to determine prognostic factors in pa-
tients with TL in prerituximab era. Some of the indicators for 
worse survival include high lactate dehydrogenase (LDH), 
advanced stage disease, and not having achieved complete 
remission.6 However, these factors did not have similar 
prognostic value in postrituximab era8,9 thus needing further 
exploration.
3.3 | Diagnosis of TL
Transformation of lymphoma is generally diagnosed by his-
tology. Transformed FL may or may not retain markers simi-
lar to its original follicular origin. Although changes in the 
antigenic marker are common, the light chain restriction is 
usually preserved. Therefore, a change of the light chain re-
striction from kappa to lambda or vice versa should raise the 
concern for a second malignancy rather than TL.1
Less commonly, clinical diagnosis of TL can be made, if 
the histological diagnosis is not feasible, based on reliable 
predictors such as rising LDH, rapid nodal growth, the in-
volvement of new extranodal sites, sudden decline in perfor-
mance status, new “B” symptoms and hypercalcemia.6,8,10 
Radiological studies, such as positron emission tomography 
(PET‐CT) scans, could be used in this regard. For PET‐CT 
scans, higher standardized uptake values (SUVs) more than 
13 is predictive of an aggressive lymphoma (sensitivity of 
90%). In addition, the positive predictive value for detecting 
TL is 100%, if SUV max is more than 17.11
3.4 | TL of follicular lymphoma to B‐
lymphoblastic leukemia/lymphoma
Acquiring MYC rearrangement is a detrimental step contrib-
uting to the development of transformed lymphoma.2,12,13 
Based on literature search, lymphoblastoid transformation of 
FL is a rare phenomenon, and Geyer et al2 reported a series of 
seven cases with an additional review of additional 20 cases 
reported in the literature, noting the various names it was 
given: Acute lymphoblastic leukemia, precursor B‐cell blast 
crisis, and atypical Burkitt lymphoma. Most FL cases carry 
t(14;18) involving BCL2 gene. Most reported cases (upward 
of 90%) of lymphoblastoid transformation of FL are dou-
ble‐hit (ie, carry both MYC and BCL2 gene rearrangement). 
While the prognosis of lymphoblastoid transformation with 
double‐hit is slightly worse than that of de novo double‐hit 
lymphoma, its unclear whether the lymphoblastoid morphol-
ogy or the double‐hit nature of this transformation confers a 
worse prognosis than what would be expected from a typi-
cal tranformation of FL to DLBCL.2 Geyer et al suggested 
the unifying term of “lymphoblastic transformation of FL.” 
However, the current WHO recommended terminology 
for either de novo double‐hit blastoid TdT+ lymphoma or 
FL transforming to blastoid TdT+ double‐hit lymphoma is 
“lymphoblastic”.14
3.5 | Ocular lymphoma
Ocular Lymphoma is the most frequent tumor of all malig-
nant ocular tumors, constituting up to 55% of all orbital tu-
mors.15 Ocular lymphomas are broadly separated into two 
main categories: intraocular lymphoma, which is mainly a 
subset of primary central nervous system lymphoma (IOL), 
and ocular adnexal Lymphoma (OAL), which are mainly 
NHL. This classification is important because of the great 
differences in natural history, management options, and 
outcomes. OAL can present in many different ways such, 
as an orbital mass, a lesion of the lacrimal gland or less fre-
quently it can involve the conjunctiva or the eyelids. Very 
rarely, OAL may present as intraocular lymphoma.16 Of 
all the OAL, marginal zone B‐cell lymphoma (MZL) and 
mucosa‐associated lymphoid tissue (MALT) lymphoma 
comprise approximately 50%. The other two more common 
reported subtypes of OAL include lymphoplasmacytic and 
follicular lymphomas.17 The outcomes for OAL is gener-
ally favorable with 5‐yearsoverall survival rate ranging 
from 50% to 94%. These data are mainly driven by the re-
ported outcomes of OAL‐MALT lymphoma. OAL has an 
overall outcome that is similar to that of its cousin, nodal 
NHL, namely better outcomes in lower grades disease. This 
similarity of ocular adnexal and its more common cousin, 
nodal lymphoma, implies no real prognostic implications 
of initial Ocular lymphoma involvement.16
3.6 | Management of TL
The management of TL is mainly derived from the evidence 
of treating FL transformed to DLBCL. The treatment, in gen-
eral, includes rituximab‐containing high‐dose chemotherapy, 
with and without autologous hematopoietic stem cell trans-
plant. It has been shown that intensification of regimens, 
including transplant, can improve survival.18 Currently, new 
methods are being explored to treat TL, one of which is ra-
dioimmunotherapy using radioisotopes labeled monoclonal 
antibodies, which seems to be promising.19
The management of ocular adnexal lymphoma on the 
other hand, given its anatomical involvement, generally in-
volves radiotherapy. While radiotherapy is the most exten-
sively employed approach, the response rates are usually 
low. Other management approaches include chemother-
apy, immunotherapy, and surgical excision followed by 
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observation.16 In our case, given the aggressive nature of 
this transformed lymphoma, we adopted a combination of 
radiation therapy to the orbit and high‐dose chemotherapy 
(HyperCVAD).
4 |  CONCLUSION
Transformation of indolent lymphoma to more aggressive 
lymphoma is an infrequent event and carries a poor prog-
nosis. TL isolated to the orbit is extremely uncommon. To 
the best of our knowledge, this is the first case report of such 
transformation of FL to B‐lymphoblastic lymphoma with a 
simultaneous MYC and BCL2 translocation (double‐hit) in 
the eye. A presentation of what seems like orbital cellulitis in 
patients with indolent lymphoma may, in fact, be a presenta-
tion of ocular lymphomatous involvement.
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